Gene
KIR3DS1
| Entrez Gene ID | 3813 (See on NCBI) |
| Description | killer cell immunoglobulin-like receptor, three domains, short cytoplasmic tail, 1 |
| Gene Synonyms | CD158E2, KIR-123FM, KIR-G1, NKAT10 |
| Node consisting of this Gene | KIR3DS1///KIR3DL1 LOC727787///KIR2DL5B///KIR2DL5A///KIR3DS1///KIR3DL2///KIR3DL1///KIR2DS5///KIR2DS1///KIR2DL4///KIR2DL3///KIR2DL2///KIR2DL1 KIR2DS2///KIR3DS1///KIR3DL1///KIR2DL3 KIR2DS2///KIR3DS1///KIR2DS5///KIR2DL4///KIR2DL3///KIR2DL2///KIR2DL1 |
Networks including this gene
| GSE10245_top8000 - GSE10245 - SiGN-BN NNSR | Gene expression differences between adenocarcinoma and squamous cell carcinoma in human NSCLC |
| GSE11121_top8000 - GSE11121 - SiGN-BN NNSR | The humoral immune system has a key prognostic impact in node-negative breast cancer |
| GSE12093_top8000 - GSE12093 - SiGN-BN NNSR | The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy |
| GSE12777_top8000 - GSE12777 - SiGN-BN NNSR | Gene expression profiling of 51 human breast cancer cell lines |
| GSE13009_top8000 - GSE13009 - SiGN-BN NNSR | MCF7 EGF, HRG stimulation |
| GSE13601_top8000 - GSE13601 - SiGN-BN NNSR | Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators |
| GSE13996_top8000 - GSE13996 - SiGN-BN NNSR | Molecular profiling of classical Hodgkin’s lymphoma tissues |
| GSE15852_top8000 - GSE15852 - SiGN-BN NNSR | Expression data from human breast tumors and their paired normal tissues |
| GSE17705_top8000 - GSE17705 - SiGN-BN NNSR | Endocrine Sensitivity Index Validation Dataset |
| GSE19069_top8000 - GSE19069 - SiGN-BN NNSR | Molecular signatures in peripheral T-cell lymphoma (PTCL) |
| GSE20181_top8000 - GSE20181 - SiGN-BN NNSR | Letrozole (Femara) early and late responses to treatment |
| GSE20189_top8000 - GSE20189 - SiGN-BN NNSR | A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma |
| GSE20194_top8000 - GSE20194 - SiGN-BN NNSR | MAQC-II Project: human breast cancer (BR) data set |
| GSE2034_top8000 - GSE2034 - SiGN-BN NNSR | Breast cancer relapse free survival |
| GSE2113_top8000 - GSE2113 - SiGN-BN NNSR | Plasma cell dyscrasias expression profiles associated with distinct IGH translocations in multiple myeloma |
| GSE22093_top8000 - GSE22093 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients |
| GSE22597_top8000 - GSE22597 - SiGN-BN NNSR | Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients |
| GSE23988_top8000 - GSE23988 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients (US samples) |
| GSE24080_top8000 - GSE24080 - SiGN-BN NNSR | MAQC-II Project: Multiple myeloma (MM) data set |
| GSE25055_top8000 - GSE25055 - SiGN-BN NNSR | Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25065_top8000 - GSE25065 - SiGN-BN NNSR | Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25066_top8000 - GSE25066 - SiGN-BN NNSR | Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE2603_top8000 - GSE2603 - SiGN-BN NNSR | Subpopulations of MDA-MB-231 and Primary Breast Cancers |
| GSE26549_top8000 - GSE26549 - SiGN-BN NNSR | Gene Expression Profiling Predicts the Development of Oral Cancer |
| GSE27562_top8000 - GSE27562 - SiGN-BN NNSR | Expression data from human PBMCs from breast cancer patients and controls |
| GSE2841_top8000 - GSE2841 - SiGN-BN NNSR | Expression Profiling of pheochromocytomas of various genetic origins |
| GSE28497_top8000 - GSE28497 - SiGN-BN NNSR | New markers for minimal residual disease detection in acute lymphoblastic leukemia |
| GSE29598_top8000 - GSE29598 - SiGN-BN NNSR | A Methodology for Utilization of Predictive Genomic Signatures in FFPE Samples |
| GSE31245_top8000 - GSE31245 - SiGN-BN NNSR | Unique gene expression profile based upon pathologic response in epithelial ovarian cancer |
| GSE3143_top8000 - GSE3143 - SiGN-BN NNSR | Breast Cancer Dataset |
| GSE3149_top8000 - GSE3149 - SiGN-BN NNSR | Ovarian Cancer Dataset |
| GSE3151_top8000 - GSE3151 - SiGN-BN NNSR | Oncogene Signature Dataset |
| GSE31519_top8000 - GSE31519 - SiGN-BN NNSR | A Clinically Relevant Gene Signature in Triple-Negative and Basal-Like Breast Cancer |
| GSE31552_top8000 - GSE31552 - SiGN-BN NNSR | Expression Data from human Lung tissue of Patients with Non Small Cell Lung Cancer (NSCLC) |
| GSE3629_top8000 - GSE3629 - SiGN-BN NNSR | Molecular Marker for predicting development of cancer in ulcerative colitis |
| GSE3726_top8000 - GSE3726 - SiGN-BN NNSR | Prognostic gene signatures can be measured with samples stored in RNAlater |
| GSE3960_top8000 - GSE3960 - SiGN-BN NNSR | Classification of neuroblastoma by integrating gene expression pattern with regional alterations in DNA copy number |
| GSE4122_top8000 - GSE4122 - SiGN-BN NNSR | Gene Expression Analysis of Ovarian Samples |
| GSE4452_top8000 - GSE4452 - SiGN-BN NNSR | Gene Expression Profiles of Multiple Myeloma (N=65) Before Treatment |
| GSE4573_top8000 - GSE4573 - SiGN-BN NNSR | Gene expression signatures for predicting prognosis of squamous cell lung carcinomas |
| GSE4581_top8000 - GSE4581 - SiGN-BN NNSR | Gene Expression Profiles of Multiple Myeloma (N=414) Before Treatment |
| GSE5327_top8000 - GSE5327 - SiGN-BN NNSR | Breast cancer relapse free survival and lung metastasis free survival |
| GSE5462_top8000 - GSE5462 - SiGN-BN NNSR | Letrozole (Femara) early response to treatment |
| GSE5851_top8000 - GSE5851 - SiGN-BN NNSR | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| GSE5900_top8000 - GSE5900 - SiGN-BN NNSR | Gene Expression of Bone Marrow Plasma Cells from Healthy Donors (N=22), MGUS (N=44), and Smoldering Myeloma (N=12) |
| GSE6008_top8000 - GSE6008 - SiGN-BN NNSR | Human ovarian tumors and normal ovaries |
| GSE6338_top8000 - GSE6338 - SiGN-BN NNSR | Gene expression analysis of Peripheral T-cell Lymphoma/Unspecified |
| GSE6462_top8000 - GSE6462 - SiGN-BN NNSR | MCF7 dose response |
| GSE6477_top8000 - GSE6477 - SiGN-BN NNSR | Expression data from different stages of plasma cell neoplasm |
| GSE7208_top8000 - GSE7208 - SiGN-BN NNSR | Expression data from 59 human colon tumor tissue samples |
| GSE7390_top8000 - GSE7390 - SiGN-BN NNSR | Strong Time Dependence of the 76-Gene Prognostic Signature |
| GSE7670_top8000 - GSE7670 - SiGN-BN NNSR | Expression data from Lung cancer |
| GSE7849_top8000 - GSE7849 - SiGN-BN NNSR | Age-Specific Differences of Oncogenic Pathway Deregulation Seen in Human Breast Tumors |
| GSE8139_top8000 - GSE8139 - SiGN-BN NNSR | Expression data from MCF7/HER2-18 xenografts |
| GSE8401_top8000 - GSE8401 - SiGN-BN NNSR | Gene Signature for Aggression of Melanoma Metastases - Melanoma Metastasis |
| GSE8481_top8000 - GSE8481 - SiGN-BN NNSR | Various human cell types |
| GSE8546_top8000 - GSE8546 - SiGN-BN NNSR | Gene Expression Changes in Myeloma Cells Following Short Term In-vivo Drug Exposure |
| GSE8581_top8000 - GSE8581 - SiGN-BN NNSR | Human Chronic Obstructive Pulmonary Disorder (COPD) Biomarker |
| GSE8835_top8000 - GSE8835 - SiGN-BN NNSR | Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. |
| GSE9992_top8000 - GSE9992 - SiGN-BN NNSR | Molecular and transcriptional characterization of chromosome 17p loss in chronic lymphocytic leukemia, experiment A |
(60 networks)
